Telix Pharmaceuticals
- Country
- 🇦🇺Australia
- Ownership
- -
- Employees
- 234
- Market Cap
- $4.5B
- Introduction
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat t...
89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT06537596
- Locations
- 🇦🇺
Precision Molecular Imaging & Theranostics Pty Ltd, Melbourne, Victoria, Australia
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT GLOBAL)
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Target Recruit Count
- 430
- Registration Number
- NCT06520345
- Locations
- 🇺🇸
Biogenix Molecular LLC, Miami, Florida, United States
🇺🇸XCancer Omaha, Omaha, Nebraska, United States
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
- Conditions
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
- Target Recruit Count
- 392
- Registration Number
- NCT04876651
- Locations
- 🇦🇺
'GenesisCare Murdoch', Murdoch, Western Australia, Australia
🇳🇿Auckland City Hospital, Auckland, New Zealand
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia